Your browser doesn't support javascript.
loading
Dengue virus IgG and serotype-specific neutralizing antibody titers measured with standard and mature viruses are associated with protection.
Katzelnick, Leah; Odio, Camila; Daag, Jedas; Crisostomo, Maria Vinna; Voirin, Charlie; Escoto, Ana Coello; Adams, Cameron; Hein, Lindsay Dahora; Aogo, Rosemary; Mpingabo, Patrick; Rodriguez, Guillermo Raimundi; Firdous, Saba; Fernandez, Maria Abad; White, Laura; Agrupis, Kristal-An; Deen, Jacqueline; de Silva, Aravinda; Ylade, Michelle.
Afiliación
  • Katzelnick L; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
  • Odio C; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
  • Daag J; Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines Manila, Manila, Philippines.
  • Crisostomo MV; Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines Manila, Manila, Philippines.
  • Voirin C; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
  • Escoto AC; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
  • Adams C; University of North Carolina at Chapel Hill.
  • Hein LD; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill.
  • Aogo R; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
  • Mpingabo P; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
  • Rodriguez GR; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
  • Firdous S; National Institute of Allergy and Infectious Diseases.
  • Fernandez MA; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill.
  • White L; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill.
  • Agrupis KA; Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines Manila.
  • Deen J; Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines Manila.
  • de Silva A; University of North Carolina at Chapel Hill.
  • Ylade M; Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines Manila.
Res Sq ; 2024 Apr 12.
Article en En | MEDLINE | ID: mdl-38659845
ABSTRACT
Recent work demonstrates the limitations of the standard dengue virus (DENV) neutralization assay to predict protection against dengue. We perform studies to compare how a commercial IgG ELISA, envelope domain III (EDIII) or non-structural protein 1 (NS1) binding antibodies, and titers from plaque reduction neutralization tests (PRNTs) using reference standard and clinical mature viruses are associated with dengue disease. Healthy children (n = 1,206) in Cebu, Philippines were followed for 5 years. High ELISA values (≥3) were associated with reduced dengue probability relative to naïve children (3% vs. 10%, p = 0.008), but antibody binding EDIII or NS1 from each serotype had no association. High standard and mature geometric mean PRNT titers were associated with reduced dengue disease overall (p < 0.01), and high DENV2 and DENV3 titers in both assays provided protection against the matched serotype (p < 0.02). However, while 52% of dengue cases had standard virus PRNT titers > 100, only 2% of cases had mature virus PRNT titers > 100 (p < 0.001), indicating a lower, more consistent threshold for protection. Each assay may be useful for different purposes as correlates of protection in population and vaccine trials.